• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

HomeNewsCelyad Announces Details of Upcoming Half Year 201…Newsroom Celyad Announces Details of Upcoming Half Year 2015 Financial Results

August 12, 2015 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (formerly known as Cardio3 BioSciences, Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced that it will report its financial results for the six months ended 30 June, 2015 on Tuesday 25 August, 2015 at 7:00am CET.

A conference all will be held on Tuesday 25 August at 2:00pm CET / 8:00am EDT to review the financial results. Christian Homsy, Chief Executive Officer, and Patrick Jeanmart, Chief Financial Officer, will deliver a brief presentation followed by a Q&A session.

Participants are asked to call the assigned number approximately five minutes before the conference call begins.

The call can be accessed by dialing the numbers below and quoting conference ID number 11186221.

Participant International Dial-In:+44 (0) 1452 555566
Belgium:0800 40 864
France:0805 632 056
United States:1 866 966 9439

Download press release(s)
Communiqué de presse
Press Release
Persbericht

Filed Under: Corporate, Regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use